Business Context and Reporting Period
This Form 8-K filing by Gossamer Bio, Inc. (GOSS) is dated September 11, 2024. The report addresses a regulatory notice received from the Nasdaq Stock Market regarding the company's compliance with continued listing standards.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on stock listing compliance.
Material Changes
The material event reported is the failure of the company's common stock to maintain a minimum bid price of $1.00 per share for 30 consecutive business days between July 30, 2024, and September 10, 2024. This deficiency violates Nasdaq Listing Rule 5450(a)(1).
Outlook, Risks, and Management Commentary
- Compliance Period: The company has been granted an initial 180-day compliance period, ending March 10, 2025, to regain compliance.
- Requirements: To comply, the closing bid price must be at least $1.00 per share for a minimum of ten consecutive business days prior to the compliance date.
- Secondary Options: If the company fails to regain compliance by March 10, 2025, it may be eligible for an additional 180-day period. This would require transferring the listing to the Nasdaq Capital Market and meeting its initial listing standards (excluding the minimum bid price), potentially via a reverse stock split.
- Risks: There is no assurance the company will regain compliance or that an appeal to a Nasdaq Hearing Panel would be successful if a delisting notice is issued.
- Management Action: Management intends to monitor the stock price and consider available options to regain compliance.
Investor Verification Checklist
- Verify the current trading price of GOSS relative to the $1.00 minimum bid price requirement.
- Monitor for any announcements regarding a reverse stock split or other capital structure changes.
- Track the company's progress toward achieving ten consecutive days of trading above $1.00 before March 10, 2025.
- Review future filings for potential delisting notices or appeals to the Nasdaq Hearing Panel.